Clobenpropit: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) Alter: issue. Formatted dashes. | Use this bot. Report bugs. | Suggested by Abductive | Category:Drugs not assigned an ATC code | #UCB_Category 742/2241 |
Entranced98 (talk | contribs) +sd |
||
Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| IUPAC_name = ''N'''-[(4-chlorophenyl)methyl]-1-[3-(3''H''-imidazol-4-yl)propylsulfanyl]formamidine |
| IUPAC_name = ''N'''-[(4-chlorophenyl)methyl]-1-[3-(3''H''-imidazol-4-yl)propylsulfanyl]formamidine |
Latest revision as of 01:31, 13 November 2022
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H17ClN4S |
Molar mass | 308.83 g·mol−1 |
3D model (JSmol) | |
|
Clobenpropit is a histamine H3 receptor antagonist.[1] It has neuroprotective effects via stimulation of GABA release in brain cells in vitro.[2]
References[edit]
- ^ Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P (2007). "The human histamine H3 receptor couples to GIRK channels in Xenopus oocytes". European Journal of Pharmacology. 567 (3): 206–210. doi:10.1016/j.ejphar.2007.04.032. PMID 17537431.
- ^ Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007). "The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons". European Journal of Pharmacology. 563 (1–3): 117–123. doi:10.1016/j.ejphar.2007.01.069. PMID 17350613.